Ambra1 modulates the sensitivity of breast cancer cells to epirubicin by regulating autophagy via ATG12.

ABSTRACT: The sensitivity of breast cancer cells to epirubicin (EPI) is closely related to the efficacy of the drug and the prognosis of patients. A growing body of research has suggested that autophagy is involved in the treatment of a variety of cancers, including breast cancer, and modifies the sensitivity of anticancer drugs. However, the mechanism by which autophagy participates in cancer therapy and modulates drug sensitivity has not been fully elucidated. In this study, we showed that the expression of Autophagy/Beclin 1 regulator 1 (Ambra1), a key protein of autophagy, was negatively correlated with EPI sensitivity in breast cancer cells. In addition, it altered the sensitivity of breast cancer cells to EPI by regulating EPI-induced autophagy. As a potential mechanism, we demonstrated that a

SUBMITTER: Sun WL 

PROVIDER: S-EPMC6172055 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature